Evaluation of the diagnostic value of peripheral BDNF levels for Alzheimer’s disease and mild cognitive impairment: results of a meta-analysis

References

• Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640–651.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66(12):1447–1455.
   PubMedGoogle Scholar
• Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61(1):59–66.
   PubMedGoogle Scholar
• Honig LS. Gene therapy in Alzheimer disease – it may be feasible, but will it be beneficial? JAMA Neurol. 2018;75(7):791.
   PubMed Web of Science ®Google Scholar
• Fyfe I. Alzheimer disease: tau pathology in atomic detail. Nat Rev Neurol. 2017;13(9):513.
   PubMed Web of Science ®Google Scholar
• Beeri MS, Sonnen J. Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression. Neurology. 2016;86(8):702–703.
   PubMed Web of Science ®Google Scholar
• Benarroch EE. Brain-derived neurotrophic factor: regulation, effects, and potential clinical relevance. Neurology. 2015;84(16):1693–1704.
   PubMed Web of Science ®Google Scholar
• Pilakka-Kanthikeel S, Atluri VS, Sagar V, et al. Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study. PLoS One. 2013;8(4):e62241.
   PubMed Web of Science ®Google Scholar
• Leyhe T, Stransky E, Eschweiler GW, et al. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2008;258(2):124–128.
   PubMed Web of Science ®Google Scholar
• Laske C, Stransky E, Leyhe T, et al. Decreased brain-derived neurotrophic factor (BDNF)- and beta-thromboglobulin (beta-TG)-blood levels in Alzheimer’s disease. Thromb Haemost. 2006;96:102–103.
   PubMed Web of Science ®Google Scholar
• Xie B, Zhou H, Zhang R, et al. Serum miR-206 and miR-132 as potential circulating biomarkers for mild cognitive impairment. J Alzheimers Dis. 2015;45(3):721–731.
   PubMed Web of Science ®Google Scholar
• Forlenza OV, Diniz BS, Teixeira AL, et al. Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry. 2010;11(6):774–780.
   PubMed Web of Science ®Google Scholar
• Passaro A, Dalla Nora E, Morieri ML, et al. Brain-derived neurotrophic factor plasma levels: relationship with dementia and diabetes in the elderly population. J Gerontol A Biol Sci Med Sci. 2015;70(3):294–302.
   PubMed Web of Science ®Google Scholar
• Leyhe T, Eschweiler GW, Stransky E, et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease. J Alzheimers Dis. 2009;16(3):649–656.
   PubMed Web of Science ®Google Scholar
• O’Bryant SE, Hobson VL, Hall JR, et al. Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer’s disease cases. Dement Geriatr Cogn Disord. 2011;31:31–36.
   PubMed Web of Science ®Google Scholar
• Balietti M, Giuli C, Fattoretti P, et al. Effect of a comprehensive intervention on plasma BDNF in patients with Alzheimer’s disease. Alzheimers Dis. 2017;57(1):37–43.
   PubMed Web of Science ®Google Scholar
• Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S. 2013. Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration, 2011. Hoboken, NJ: Wiley-Blackwell. Available from: www.handbook.cochrane.org
   Google Scholar
• Prema A, Justin Thenmozhi A, Manivasagam T, et al. Fenugreek seed powder attenuated aluminum chloride-induced tau pathology, oxidative stress, and inflammation in a rat model of Alzheimer’s disease. J Alzheimers Dis. 2017;60(s1):S209–S220.
   PubMed Web of Science ®Google Scholar
• Durand D, Carniglia L, Turati J, et al. Amyloid-beta neurotoxicity and clearance are both regulated by glial group II metabotropic glutamate receptors. Neuropharmacology. 2017;123:274–286.
   PubMed Web of Science ®Google Scholar
• Alvarez A, Aleixandre M, Linares C, et al. Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer’s disease. J Alzheimers Dis. 2014;42(4):1347–1355.
   PubMed Web of Science ®Google Scholar
• Borba EM, Duarte JA, Bristot G, et al. Brain-derived neurotrophic factor serum levels and hippocampal volume in mild cognitive impairment and dementia due to Alzheimer disease. Dement Geriatr Cogn Dis Extra. 2016;6(3):559–567.
   PubMed Web of Science ®Google Scholar
• Coelho FG, Vital TM, Stein AM, et al. Acute aerobic exercise increases brain-derived neurotrophic factor levels in elderly with Alzheimer’s disease. J Alzheimers Dis. 2014;39(2):401–408.
   PubMed Web of Science ®Google Scholar
• Curto M, Martocchia A, Comite F, et al. The presence of depressive symptoms in comorbidity with Alzheimer’s disease does not influence changes in serum brain-derived neurotrophic factor levels in older patients. Int J Geriatr Psychiatry. 2014;29(4):439–440.
   PubMed Web of Science ®Google Scholar
• Angelucci F, Spalletta G, di Iulio F, et al. Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res. 2010;7(1):15–20.
   PubMed Web of Science ®Google Scholar
• Forlenza OV, Miranda AS, Guimar I, et al. Decreased neurotrophic support is associated with cognitive decline in non-demented subjects. J Alzheimers Dis. 2015;46(2):423–429.
   PubMed Web of Science ®Google Scholar
• Kim BY, Lee SH, Graham PL, et al. Peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease and mild cognitive impairment: a comprehensive systematic review and meta-analysis. Mol Neurobiol. 2017;54(9):7297–7311.
   PubMed Web of Science ®Google Scholar
• Ziegenhorn AA, Schulte-Herbruggen O, Danker-Hopfe H, et al. Serum neurotrophins – a study on the time course and influencing factors in a large old age sample. Neurobiol Aging. 2007;28(9):1436–1445.
   PubMed Web of Science ®Google Scholar
• Qin XY, Cao C, Cawley NX, et al. Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease: a meta-analysis study (N = 7277). Mol Psychiatry. 2017;22(2):312–320.
   PubMed Web of Science ®Google Scholar
• Diniz BS, Teixeira AL, Machado-Vieira R, et al. Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression. J Gerontol B Psychol Sci Soc Sci. 2014;69(6):845–851.
   PubMed Web of Science ®Google Scholar
• Faria MC, Goncalves GS, Rocha NP, et al. Increased plasma levels of BDNF and inflammatory markers in Alzheimer’s disease. J Psychiatr Res. 2014;53:166–172.
   PubMed Web of Science ®Google Scholar
• Konukoglu D, Andican G, Firtina S, et al. Serum brain-derived neurotrophic factor, nerve growth factor and neurotrophin-3 levels in dementia. Acta Neurol Belg. 2012;112(3):255–260.
   PubMed Web of Science ®Google Scholar
• Laske C, Stransky E, Eschweiler G, et al. BDNF serum concentrations in patients with Alzheimer’s disease are associated with depressive mood states. Neurol Psychiatr Brain Res. 2005;12:1–4.
   Google Scholar
• Laske C, Stransky E, Leyhe T, et al. Stage-dependent BDNF serum concentrations in Alzheimer’s disease. J Neural Transm. 2006;113(9):1217–1224.
   PubMed Web of Science ®Google Scholar
• Laske C, Stransky E, Leyhe T, et al. BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 2007;41(5):387–394.
   PubMed Web of Science ®Google Scholar
• Lee JG, Shin BS, You YS, et al. Decreased serum brain-derived neurotrophic factor levels in elderly Korean with dementia. Psychiatry Investig. 2009;6(4):299–305.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Baek JH, Kim YH. Brain-derived neurotrophic factor is associated with cognitive impairment in elderly Korean individuals. Clin Psychopharmacol Neurosci. 2015;13(3):283–287.
   PubMed Web of Science ®Google Scholar
• Liu YH, Jiao SS, Wang YR, et al. Associations between ApoEepsilon4 carrier status and serum BDNF levels – new insights into the molecular mechanism of ApoEepsilon4 actions in Alzheimer’s disease. Mol Neurobiol. 2015;51(3):1271–1277.
   PubMed Web of Science ®Google Scholar
• Nascimento CM, Pereira JR, de Andrade LP, et al. Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr Alzheimer Res. 2014;11(8):799–805.
   PubMed Web of Science ®Google Scholar
• O’Bryant SE, Hobson V, Hall JR, et al. Brain-derived neurotrophic factor levels in Alzheimer’s disease. J Alzheimers Dis. 2009;17:337–341.
   PubMed Web of Science ®Google Scholar
• Shimada H, Makizako H, Doi T, et al. A large, cross-sectional observational study of serum BDNF, cognitive function, and mild cognitive impairment in the elderly. Front Aging Neurosci. 2014;6:69.
   PubMed Web of Science ®Google Scholar
• Siuda J, Patalong-Ogiewa M, Zmuda W, et al. Cognitive impairment and BDNF serum levels. Neurol Neurochir Pol. 2017;51(1):24–32.
   PubMed Web of Science ®Google Scholar
• Sonali N, Tripathi M, Sagar R, et al. Val66Met polymorphism and BDNF levels in Alzheimer’s disease patients in North Indian population. Int J Neurosci. 2013;123(6):409–416.
   PubMed Web of Science ®Google Scholar
• Turana Y, Ranakusuma TA, Purba JS, et al. Enhancing diagnostic accuracy of a MCI in the elderly: combination of olfactory test, pupillary response test, BDNF plasma level, and APOE genotype. Int J Alzheimers Dis. 2014;2014:912586.
   PubMedGoogle Scholar
• Ventriglia M, Zanardini R, Bonomini C, et al. Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed Res Int. 2013;2013:901082.
   PubMed Web of Science ®Google Scholar
• Yasutake C. Serum BDNF, TNF-α and IL-1β levels in dementia patients. Eur Arch Psychiatry Clin Neurosci. 2006;256(7):406.
   PubMed Web of Science ®Google Scholar
• Yu H, Zhang Z, Shi Y, et al. Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. J Clin Psychiatry. 2008;69(7):1104–1111.
   PubMed Web of Science ®Google Scholar
• Wang C, Cui Y, Yang J, et al. Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer’s disease in patients with the apolipoprotein E4 genotype. Biomarkers. 2015;20(1):84–88.
   PubMed Web of Science ®Google Scholar
• Zheng L, Kong X, Cui Y, et al. Conversion from MCI to AD in patients with the APOE ε4 genotype: prediction by plasma HCY and serum BDNF. Neurosci Lett. 2016;626:19–24.
   PubMed Web of Science ®Google Scholar